High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C

BACKGROUND: High prices of direct acting antivirals (DAAs) for hepatitis C virus (HCV) can lead to restrictions on access to treatment in high- and middle-income countries. An increasing number of people in these countries are treating their HCV infection with generic drugs produced in India, China,...

詳細記述

保存先:
書誌詳細
出版年:J Virus Erad
主要な著者: Hill, Andrew, Khwairakpam, Giten, Wang, James, Golovin, Sergey, Dragunova, Julia, Smith, Rachel, Houghton-Price, Vicky, Korologou-Linden, Roxanna, Nath, Sanjay, Savage, Anna, Jefferys, Greg
フォーマット: Artigo
言語:Inglês
出版事項: Mediscript Ltd 2017
主題:
Original Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5632545/
https://ncbi.nlm.nih.gov/pubmed/29057082
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料